Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

被引：19

作者：

Kindler, Hedy L.

Scherpereel, Arnaud

Calabro, Luana

Aerts, Joachim

Perez, Susana Cedres

Bearz, Alessandra

Nackaerts, Kristiaan

Fennell, Dean Anthony

Kowalski, Dariusz

Tsao, Anne S.

Taylor, Paul

Grosso, Federica

Antonia, Scott Joseph

Nowak, Anna K.

Ibrahim, Ramy A.

Taboada, Maria

Puglisi, Martina

Stockman, Paul K.

Maio, Michele

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] CHRU Lille, Hop Albert Calmette, Lille, France

[3] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy

[4] Erasmus MC, Rotterdam, Netherlands

[5] Vall Hebron Univ Hosp, Barcelona, Spain

[6] Ctr Riferimento Oncol Aviano, Pordenone, Italy

[7] KU Leuven Univ Leuven, Leuven, Belgium

[8] Univ Hosp Leicester, Leicester, Leics, England

[9] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Hosp South Manchester, North West Lung Ctr, Manchester, Lancs, England

[12] SS Antonio & Biagio Gen Hosp, Oncol, Alessandria, Italy

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] AstraZeneca, Gaithersburg, MD USA

[16] AstraZeneca, Alderley Pk, England

[17] AstraZeneca, Cambridge, England

[18] Univ Hosp Siena, Siena, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.8502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8502

引用

页数：2